News

The company has also requested priority review of its application and, if granted, Clolar could be approved for this indication in the first half of 2009. Genzyme’s supplemental

Most recently, Mr Pinon was CEO of Bioheart, a biotechnology company focused on the development of heart failure therapies and devices. Prior to Bioheart, Mr Pinon held a

Labopharm’s new drug application (NDA) for its novel trazodone formulation is based on data from five pivotal pharmacokinetic studies and the positive results from its North American Phase

Mr Vaello brings more than 15 years of sales expertise in the oncology and imaging industries to TomoTherapy, where he will be responsible for enhancing sales performance and

Previously, Mr King has served as the CEO of Principia Pharmaceutical, which was acquired by Human Genome Sciences, and as president of Delsys Pharmaceutical, which was acquired by

The Phase Ib clinical trial is designed to primarily evaluate the safety and tolerability of repeated dosing of MDX-1106 in adult patients with solid tumors and will also

Similar to the treatment week 12 results reported earlier in 2008, the 48-week viral response data continue to show comparable reductions in viral load for weight-based doses of

Poniard is developing picoplatin, its lead product candidate, as a potential new platform product for the treatment of solid tumors. The company is evaluating picoplatin in four clinical

The FIXFc compound is a recombinant protein in early-stage development for the treatment of hemophilia B. The Fc fusion with Factor IX is intended to prolong the effect